[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580146":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":34,"locations":40,"responsibleParty":75,"collaborators":77,"id":80,"slug":26,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":26,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":26,"enrollmentInfo":88,"targetDuration":26,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":26,"overallStatus":42,"whyStopped":26,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"H. Lee Moffitt Cancer Center and Research Institute","OTHER",[8,13,17],{"label":9,"type":6,"description":10,"interventionNames":11},"Triple negative","Participants diagnosed with triple negative breast cancer.",[12],"Other: CT Scan",{"label":14,"type":6,"description":15,"interventionNames":16},"HER2+","Participants diagnosed with HER2+ breast cancer.",[12],{"label":18,"type":6,"description":19,"interventionNames":20},"Hormone receptor (HR)+","Participants diagnosed with hormone receptor (HR)+ breast cancer.",[12],[22],{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"CT Scan","Participants will undergo a screening CT thorax, abdomen, pelvis at baseline prior to adjuvant radiation therapy and additional screening CT thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.",[14,18,9],null,[28,32],{"name":29,"affiliation":30,"role":31},"Kamran Ahmed","Moffitt Cancer Center","PRINCIPAL_INVESTIGATOR",{"name":33,"affiliation":30,"role":31},"Matthew Mills",[35],{"name":36,"role":37,"phone":38,"phoneExt":26,"email":39},"Marian Hernandez","CONTACT","813-745-1807","marian.hernandez@moffitt.org",[41],{"facility":30,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Tampa","Florida","33612","United States",{"type":48,"coordinates":49},"Point",[50,51],-82.45843,27.94752,{"lat":51,"lon":50},[54,56,58,61,63,65,67,69,71,73],{"name":55,"role":31,"phone":26,"phoneExt":26,"email":26},"Kamran Ahmed, MD",{"name":57,"role":31,"phone":26,"phoneExt":26,"email":26},"Matthew Mills, MD",{"name":59,"role":60,"phone":26,"phoneExt":26,"email":26},"Avan Armaghani, MD","SUB_INVESTIGATOR",{"name":62,"role":60,"phone":26,"phoneExt":26,"email":26},"Ricardo Costa, MD",{"name":64,"role":60,"phone":26,"phoneExt":26,"email":26},"Roberto Diaz, MD, PhD",{"name":66,"role":60,"phone":26,"phoneExt":26,"email":26},"Loretta Loftus, MD",{"name":68,"role":60,"phone":26,"phoneExt":26,"email":26},"Tracey O'Connor, MD",{"name":70,"role":60,"phone":26,"phoneExt":26,"email":26},"Hatem Soliman, MD",{"name":72,"role":60,"phone":26,"phoneExt":26,"email":26},"Aixa Soyano Muller, MD",{"name":74,"role":60,"phone":26,"phoneExt":26,"email":26},"Iman Washington, MD",{"type":76,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[78],{"name":79,"class":6},"Florida Breast Cancer Foundation","100580146",false,"NCT06833502","Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer","Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer Following Neoadjuvant Chemotherapy and Surgery","Inclusion Criteria:\n\n* Histologic diagnosis of breast cancer with documentation of ER\u002FPR\u002FHER2 status.\n* HR+ will be defined as ER and\u002For PR ≥ 10%. To be classified as HER2+ disease, overexpression of HER2 by either IHC or in-situ hybridization is necessary as defined by the ASCO \u002F CAP Guidelines27. Triple negative will be classified as ER and PR \\\u003C10% and HER2-.\n* Node positive HER2+ and triple negative breast cancer (ypN+) following receipt of neoadjuvant chemotherapy. HR+\u002FHER2- patients should have ypN2 or ypN3 disease following receipt of neoadjuvant chemotherapy and surgery.\n* Patient must have completed a minimum of 8 weeks of standard neoadjuvant chemotherapy consisting of an anthracycline and\u002For taxane-based regimen. To include HER2 directed therapy for HER2+ patients.\n* Age ≥ 18.\n* Life expectancy ≥ 6 months.\n* Eastern Cooperative Oncology Group performance status 0 to 2.\n* Patients must be able to understand and the willingness to sign an informed consent for study procedures.\n* Ability to understand and stated willingness to comply with all study procedures and availability for the duration of the study.\n\nExclusion Criteria:\n\n* Prior diagnosis of systemic metastases.\n* Patients with prior history of non-breast cancer malignancies should have NED ≥ 2 years excluding adequately treated non-melanoma skin cancer, in situ cancer of the cervix or bladder.\n* Contraindication towards CT IV contrast.\n* Chronic kidney disease stage IV or V or end stage renal disease (CrCl \\\u003C30 ml\u002Fmin).","ALL","18 Years",{"count":89,"type":90},120,"ESTIMATED","INTERVENTIONAL",[93],"PHASE2","The purpose of the study is to determine the frequency of systemic metastasis in node positive breast cancer following chemotherapy and surgery. Participants will be asked to spend about 6 months in this study. Participants will undergo a computed tomography (CT) screening of the thorax, abdomen, and pelvis at baseline prior to adjuvant radiation therapy and another CT screening of the thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.",[96,97],"Breast Cancer","Node-positive Breast Cancer","2026-06-30",{"date":100,"type":101},"2026-07-02","ACTUAL",{"date":103,"type":101},"2025-02-24",{"date":105,"type":90},"2026-10",{"name":5,"class":6},1]